The firm has unveiled new systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics.

Alinity systems, which feature common software and hardware, can work together to provide greater capacity and simplify user experience.

Most of the platforms have been designed to run more tests in less space and generate test results faster, as well as minimize human errors.

Abbott said that it expects to begin Alinity launches later this year and continue into 2017.

Abbott executive vice president Brian Blaser said: "Abbott's Alinity portfolio is unprecedented in the industry.

"With our unified family of testing instruments, we'll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care."

Abbott diagnostics products research and development vice president Dr Dennis Gilbert said: "Abbott's Alinity systems are being built from the ground up based on customer insights, using the latest technologies suitable for testing today and in the future.”

In April, Abbott agreed to acquire medical device firm St. Jude Medical for about $25bn.

Based in St. Paul of Minnesota, St. Jude Medical has five product segments including heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management and cardiovascular.